公司自成立以来，本着“以缔造人类可持续健康为宗旨，以科技创新为动力”，凭借优秀的产品研发能力，经过多年的不断自主创新、持续创新和加速发展，逐步成为国内BIO领域微生态健康行业的创新企业。
2015年4月29日，WHO（世界卫生组织）发布了一份题为《世界各地国家情况分析：应对抗微生物耐药性》的新报告。这份全球首份耐药性监控报告指出，抗生素耐药性正严重威胁全球公共健康，基于对抗常见或严重疾病抗生素耐药性的分析，诸多传染病原正在产生耐药性，这将直接导致病人患病时间更长，并增加其死亡风险。
中国是世界上滥用抗生素问题最严重的国家之一。统计资料显示，平均而言，中国每人每年使用138克抗生素，是美国的10倍；约75%的季节性流感患者使用抗生素，住院患者抗生素处方率高达80%（世卫组织推荐的处方率为30%）；约97%的手术患者被给予抗生素治疗。
世界正在迈向“后抗生素时代”，面对抗生素耐药性（AMR）问题日益严峻，严重威胁全球公共健康和国家安全，各国政府意识到目前应采取措施以阻止这场未来灾难，而不知道应该“做什么”和“怎么做”的彷徨之际，沈阳惠美仁生物制品有限公司总经理兼惠美仁R&D中心研发团队带头人崔泰兴先生率先创新性地提出了以“抗生素为首的传统‘杀菌消炎’治疗的泛滥，益菌害菌通杀是违背自然规律的行为，引发了一场触目惊心的人体医疗生态灾难”；尖锐地指出了“抗生素耐药性”是这场人体医疗生态灾难的必然产物，该观点与世界卫生组织（WHO）负责卫生安全和环境事务的助理总干事福田敬二博士观点不谋而合。在此基础上，崔泰兴先生大胆提出了生态灾难必须以生态方法解决的创新指导思想和研究方向；与时俱进地推出了解决其中妇科生态灾难的切实可行的新型微生态生物制剂【善玉菌冻干活性因子】产品，成为了全行业备受瞩目的焦点企业和备受社会认可和赞赏的责任企业。
现自主研发的【E菌妇自洁】妇科生殖系统系列、【E菌肤自洁】皮肤系统系列、【E菌血自洁】循环系统系列、【E菌肺自洁】呼吸系统系列、【E菌口自洁】、【E菌胃自洁】、【E菌肠自洁】及【E菌肛自洁】消化系统黏膜系列等全系统产品，在“抗生素耐药性”的控制对策和治理“人体医疗生态灾难”的公共健康方面，取得了重大的进展。其中，部分产品已收到了良好的市场反应和效果，并以其广阔的市场空间、核心技术优势及投资价值受到了众多投资机构和海内外资本的青睐。
基于其对中国妇幼健康领域的杰出贡献， 2012年“中华妇幼健康大会”授予公司总经理崔泰兴先生为“全国妇幼健康行业十大领军人物”荣誉称号；公司拳头产品【E菌妇自洁】也被确定为“中华妇幼健康大会重点推荐产品”；沈阳惠美仁生物制品有限公司也成为国内微生态健康领域的焦点企业和备受社会认可和赞赏的责任型企业。
Shenyang HuiMeiRen Biological Products Co., Ltd. is located in the Daoyi national economic and technological development Zone in Shenyang, Liaoning, China. HuiMeiRen is a high-tech enterprise, integrating R&D, manufacturing, and marketing of new probiotic products as a whole. Since its inception, HuiMeiRen has been aiming at creation of a sustainable health. Powered by scientific and technological innovations, HuiMeiRen has gradually become one of the relevant domestic industry leaders after years of continuous innovation and accelerated development.
The company’s Philosophy is that ecological disaster must be solved by ecological methods. Aiming at creation of a sustainable health, HuiMeiRen has been developing and manufacturing new types of the world advanced ecological products.
Facing the issue of antibiotic resistance, which is threatening the global stability and national security, people are urgently aware of the necessity of actions for prevention of this future disaster. However, there has been no clear idea about the actions, specially, in terms of “what to do” and “how to do” in this case. On this occasion of hesitation, Mr. Taixing Cui, the CEO and team leader of R&D center at HuiMeiRen, first pointed out innovatively that the traditional bactericidal anti-inflammatory therapy with antibiotics results in abuse of treatment by killing both beneficial and harmful bacteria simultaneously. Furthermore, it gives rise to a shocking ecological disaster in gynecology due to contrary to the laws of nature. Under this circumstance, Mr. Cui presented its innovative guiding ideology as a solution, which the ecological disaster must be solved by an ecological method. In the meanwhile, HuiMeiRen launched its series of probiotic products-【Shan Yu Jun Lyophilized Active Factor】as a practical solution of the disaster. Therefore, HuiMeiRen becomes a star enterprise, drawing broad industry-wide attentions.
Based on his outstanding contribution to the field of maternal and child health, Chinese Journal of Woman and Child Health Assembly in 2012 granted the honorary title “Top Ten national maternal and child health industry leaders” to Mr. Taixing Cui, the CEO of HuiMeiRen.
总经理：崔泰兴
◎ 全国妇幼健康行业十大领军人物
◎ 1984-1988. 就读于辽宁大学生物学专业
◎ 1988-2000. 时任沈阳市生物化学制药厂工程师
◎ 2001-2003. 时任日本国BMG株式会社制药研究员，作为日本京都大学再生医学研究所共同研究员参加多项科研项目，担任细胞培养和动物实验工作。
